β-Thalassemia intermedia: A bird'S-eye view;β-Talasemi i̇ntermedya: Kuşbaki{dotless}şi{dotless}

Turkish Journal of Hematology

Volumn 31, Issue 1, 2014, Pages 5-16

  Haddad, Anthony ^a   Tyan, Paul ^a   Radwan, Amr ^a   Mallat, Naji ^a   Taher, Ali ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Ineffective erythropoiesis; Iron chelation; Iron overload; Thalassemia; Thalassemia intermedia

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; BOSENTAN; CALCIUM; DEFERASIROX; DEFERIPRONE; HYDROXYUREA; LOW MOLECULAR WEIGHT HEPARIN; PENTOXIFYLLINE; SILDENAFIL; ZINC;

ANEMIA; BONE DISEASE; BRAIN INFARCTION; BRAIN PSEUDOTUMOR; CONTROLLED CLINICAL TRIAL (TOPIC); ENDOCRINE DISEASE; EXTRAMEDULLARY HEMATOPOIESIS; FERRITIN BLOOD LEVEL; FIBROSIS; HORMONAL THERAPY; HUMAN; IRON CHELATION; IRON OVERLOAD; LEG ULCER; LIVER CANCER; LIVER CIRRHOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; RISK FACTOR; SPLENOMEGALY; THALASSEMIA INTERMEDIA; THROMBOCYTOSIS; THROMBOSIS; TRANSFUSION; VITAMIN SUPPLEMENTATION;

EID: 84905868087     PISSN: 13007777     EISSN: 13085263     Source Type: Journal    
DOI: 10.4274/Tjh.2014.0032     Document Type: Review

References (110)

1. Cooley TB, Lee P. A series of cases of splenomegaly in children and peculiar changes in bones; report of cases. Am J Dis Child 1927;34:347-363.
2. Whipple GH, Bradford WL. Mediterranean disease-"thalassemia" (erythroblastic anemia of Cooley): associated pigment abnormalities simulating hemochromatosis. J Pediatr 1936;9:279-311.
3. Ingram VM, Stretton AO. Genetic basis of the thalassaemia diseases. Nature 1959;184:1903-1909.
4. Weatherall DJ. Thalassemia: the long road from the bedside through the laboratory to the community. Transfus Med 2011;21:218-223.
5. Weatherall DJ, Clegg JB, Naughton MA. Globin synthesis in thalassaemia: an in vitro study. Nature 1965;208:1061-1065.
6. Weatherall DJ. The thalassemia syndromes. Tex Rep Biol Med 1980;40:323-333.
7. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-1146.
8. Sturgeon P, Itano HA, Bergren WR. Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol 1955;1:264-277.
9. Cao A, Kan YW. The prevention of thalassemia. Cold Spring Harb Perspect Med 2013;3:a011775.
10. Cappellini MD, Musallam KM, Cesaretti C, Taher A. Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. Genoa, Italy, Forum Service Editore, 2009.
11. Galanello R, Cao A. Relationship between genotype and phenotype. Thalassemia intermedia. Ann N Y Acad Sci 1998;850:325-333.
12. Weatherall DJ. Thalassaemia: the long road from bedside to genome. Nat Rev Genet 2004;5:625-631.
13. Camaschella C, Mazza U, Roetto A, Gottardi E, Parziale A, Travi M, Fattore S, Bacchiega D, Fiorelli G, Cappellini MD. Genetic interactions in thalassemia intermedia: analysis of β-mutations, alpha-genotype, gamma-promoters, and β-LCR hypersensitive sites 2 and 4 in Italian patients. Am J Hematol 1995;48:82-87.
14. Olivieri NF. The β-thalassemias. N Engl J Med 1999;341:99-109.
15. Cappellini M, Musallam K, Cesaretti C, Taher A. Thalassemia intermedia. In: Disorders of Erythropoiesis, Erythrocytes and Iron Metabolism. Genoa, Italy, Forum Service Editore, 2009.
16. Camaschella C, Cappellini MD. Thalassemia intermedia. Haematologica 1995;80:58-68.
17. Cappellini MD, Cerino M, Marelli S, Fiorelli G. Thalassemia intermedia: clinical aspects and management. Haematologica 2001;86:194-196.
18. Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol 2009;147:634-640.
19. Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G, Nemeth E. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 2007;92:583-588.
20. Hershko C. Pathogenesis and management of iron toxicity in thalassemia. Ann N Y Acad Sci 2010;1202:1-9.
21. Musallam KM, Cappellini MD, Wood JC, Motta I, Graziadei G, Tamim H, Taher AT. Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia. Haematologica 2011;96:1605-1612.
22. Musallam KM, Cappellini MD, Daar S, Karimi M, El-Beshlawy A, Taher AT. Serum ferritin levels and morbidity in beta thalassemia intermedia: a 10-year cohort study [abstract]. Blood 2012;120:1021.
23. Musallam KM, Taher AT, Rachmilewitz EA. β-Thalassemia intermedia: a clinical perspective. Cold Spring Harb Perspect Med 2012;2:a013482.
24. Musallam KM, Motta I, Salvatori M, Fraquelli M, Marcon A, Taher AT, Cappellini MD. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells Mol Dis 2012;49:136-139.
25. Maakaron JE, Cappellini MD, Graziadei G, Ayache JB, Taher AT. Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. Ann Hepatol 2013;12:142-146.
26. Taher A, Isma'Eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006;37:12-20.
27. Dore F, Cianciulli P, Rovasio S, Oggiano L, Bonfigli S, Murineddu M, Pardini S, Simonetti G, Gualdi G, Papa G. Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. Ann Ital Med Int 1992;7:137-140.
28. Aessopos A, Tassiopoulos S, Farmakis D, Moyssakis I, Kati M, Polonifi K, Tsironi M. Extramedullary hematopoiesisrelated pleural effusion: the case of β-thalassemia. Ann Thorac Surg 2006;81:2037-2043.
29. Chuang CK, Chu SH, Fang JT, Wu JH. Adrenal extramedullary hematopoietic tumor in a patient with β-thalassemia. J Formos Med Assoc 1998;97:431-433.
30. Kumar A, Aggarwal S, de Tilly LN. Case of the season. Thalassemia major with extramedullary hematopoiesis in the liver. Semin Roentgenol 1995;30:99-101.
31. Brannan D. Extramedullary hematopoiesis in anemias. Bull Johns Hopkins Hosp 1927;41:104-135.
32. Ross P, Logan W. Roentgen findings in extramedullary hematopoiesis. AJR Am J Roentgenol 1969;106:604-613.
33. Logothetis J, Constantoulakis M, Economidou J, Stefanis C, Hakas P, Augoustaki O, Sofroniadou K, Loewenson R, Bilek M. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology 1972;22:249-304.
34. Prabhakar S, Chopra J, Khosla VK, Dash S, Banerijee AK. Spinal compression in homozygous β thalassemia. Surg Neurol 1980;13:351-354.
35. Shin KH, Sharma S, Gregoritch SJ, Lifeso RM, Bettigole R, Yoon SS. Combined radiotherapeutic and surgical management of a spinal cord compression by extramedullary hematopoiesis in a patient with hemoglobin E β-thalassemia. Acta Haematol 1994;91:154-157.
36. Parsa K, Oreizy A. Nonsurgical approach to paraparesis due to extramedullary hematopoiesis. J Neurosurg 1995;82:657-660.
37. Richter E. Extramedullary hematopoiesis with intraspinal extension in thalassemia. Aktuelle Radiol 1993;3:320-322.
38. Dore F, Pardini S, Gaviano E, Longinotti M, Bonfigli S, Rovasio S, Tomiselli A, Cossu F. Recurrence of spinal cord compression from extramedullary hematopoiesis in thalassemia intermedia treated with low doses of radiotherapy. Am J Hematol 1993;44:148.
39. Salehi SA, Koski T, Ondra SL. Spinal cord compression in β-thalassemia: case report and review of the literature. Spinal Cord 2004;42:117-123.
40. Haidar R, Mhaidli H, Taher AT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J 2010;19:871-878.
41. Gimmon Z, Wexler MR, Rachmilewitz EA. Juvenile leg ulceration in β-thalassemia major and intermedia. Plast Reconstr Surg 1982;69:320-325.
42. Levin C, Koren A. Healing of refractory leg ulcer in a patient with thalassemia intermedia and hypercoagulability after 14 years of unresponsive therapy. IMAJ 2011;13:316-318.
43. Galanello R, Barella S, Turco MP, Giagu N, Cao A, Dore F, Liberato NL, Guarnone R, Barosi G. Serum erythropoietin and erythropoiesis in high-and low-fetal hemoglobin β-thalassemia intermedia patients. Blood 1994;83:561-565.
44. Brandt HRC, De Lorenzo Messina MC, Hirayama JT, Belda W Jr, Benabou JE, Criado PR. Prevalence of thrombophilia associated with leg ulcers. Br J Dermatol 2009;160:202-203.
45. Taher A, Isma'Eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, Cappellini MD. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006;96:488-491.
46. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev 2008;22:283-292.
47. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010;115:1886-1892.
48. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 2009;114:2861-2868.
49. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000;111:467-473.
50. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned M, Cesaretti C, Cappellini MD. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010;8:2152-2158.
51. Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol 1999;173:1477-1480.
52. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010;8:54-59.
53. Taher AT, Musallam KM, Wood JC, Cappellini MD. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Am J Hematol 2010;85:288-290.
54. Origa R, Barella S, Argiolas GM, Bina P, Agus A, Galanello R. No evidence of cardiac iron in 20 never-or minimallytransfused patients with thalassemia intermedia. Haematologica 2008;93:1095-1096.
55. Li X, Jankovic J, Le W. Iron chelation and neuroprotection in neurodegenerative diseases. J Neural Transm 2011;118:473-477.
56. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008;359:2254-2265.
57. Gladwin MT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. Nat Med 2003;9:496-500.
58. Aessopos A, Farmakis D, Tsironi M, Diamanti-Kandarakis E, Matzourani M, Fragodimiri C, Hatziliami A, Karagiorga M. Endothelial function and arterial stiffness in sicklethalassemia patients. Atherosclerosis 2007;191:427-432.
59. Sonakul D, Pacharee P, Laohapand T, Fucharoen S, Wasi P. Pulmonary artery obstruction in thalassaemia. Southeast Asian J Trop Med Public Health 1980;11:516-523.
60. Sumiyoshi A, Thakerngpol K, Sonakul D. Pulmonary microthromboemboli in thalassemic cases. Southeast Asian J Trop Med Public Health 1992;23:29-31.
61. Atichartakarn V, Likittanasombat K, Chuncharunee S, Chandanamattha P, Worapongpaiboon S, Angchaisuksiri P, Aryurachai K. Pulmonary arterial hypertension in previously splenectomized patients with β-thalassemic disorders. Int J Hematol 2003;78:139-145.
62. Phrommintikul A, Sukonthasarn A, Kanjanavanit R, Nawarawong W. Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia. Heart 2006;92:1467-1472.
63. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia. Haematologica 2008;93:941-942.
64. Derchi G, Galanello R, Bina P, Cappellini MD, Piga A, Lai ME, Quarta A, Casu G, Perrotta S, Pinto V, Musallam KM, Forni GL; Webthal Pulmonary Arterial Hypertension Group. Prevalence and risk factors for pulmonary arterial hypertension in a large group of β-thalassemia patients using right heart catheterization: A Webthal ® Study. Circulation 2014;129:338-345.
65. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med 1995;332:647-655.
66. Tanaka T, Miyata T, Inagi R, Kurokawa K, Adler S, Fujita T, Nangaku M. Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. Kidney Int 2003;64:2020-2032.
67. Khan S, Cleveland RP, Koch CJ, Schelling JR. Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. Lab Invest 1999;79:1089-1099.
68. Heyman SN, Khamaisi M, Rosen S, Rosenberger C. Renal parenchymal hypoxia, hypoxia response and the progression of chronic kidney disease. Am J Nephrol 2008;28:998-1006.
69. Norman JT, Orphanides C, Garcia P, Fine LG. Hypoxiainduced changes in extracellular matrix metabolism in renal cells. Exp Nephrol 1999;7:463-469.
70. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351-2366.
71. Zeisberg M, Strutz F, Müller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 2000;13(Suppl 3):111-120.
72. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006;17:17-25.
73. Ricchi P, Ammirabile M, Costantini S, Di Matola T, Spasiano A, Genna ML, Cinque P, Prossomariti L. Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: a retrospective study. Blood Cells Mol Dis 2012;49:133-135.
74. Quinn CT, Johnson VL, Kim HY, Trachtenberg F, Vogiatzi MG, Kwiatkowski JL, Neufeld EJ, Fung E, Oliveri N, Kirby M, Giardina PJ; Thalassemia Clinical Research Network. Renal dysfunction in patients with thalassaemia. Br J Haematol 2011;153:111-117.
75. Mastrangelo F, Lopez T, Rizzelli S, Manisco G, Corlianò C, Alfonso L. Function of the kidney in adult patients with Cooley's disease: a preliminary report. Nephron 1975;14:229-236.
76. Davis LE, Hohimer AR. Hemodynamics and organ blood flow in fetal sheep subjected to chronic anemia. Am J Physiol 1991;261:R1542-R1548.
77. Lafferty HM, Anderson S, Brenner BM. Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease. Am J Kidney Dis 1991;17(Suppl 1):2-7.
78. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int 1996;49:1774-1777.
79. Ponticelli C, Musallam KM, Cianciulli P, Cappellini MD. Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 2010;24:239-244.
80. Sumboonnanonda A, Malasit P, Tanphaichitr VS, Ongajyooth S, Petrarat S, Vongjirad A. Renal tubular dysfunction in alpha-thalassemia. Pediatr Nephrol 2003;18:257-260.
81. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990;186:1-85.
82. Maakaron JE, Cappellini MD, Taher AT. An update on thalassemia intermedia. J Med Liban 2013;61:175-182.
83. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, Saned MS, Graziadei G, Cappellini MD. Agerelated complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010;150:486-489.
84. Musallam KM, Khoury B, Abi-Habib R, Bazzi L, Succar J, Halawi R, Hankir A, Koussa S, Taher AT. Health-related quality of life in adults with transfusion-independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Haematol 2011;87:73-79.
85. Musallam KM, Taher AT, Duca L, Cesaretti C, Halawi R, Cappellini MD. Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusionindependent patients with β thalassemia intermedia. Blood Cells Mol Dis 2011;47:232-234.
86. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of beta thalassaemia intermedia. Br J Haematol 2011;152:512-523.
87. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007;138:291-304.
88. Borgna-Pignatti C, Marsella M, Zanforlin N. The natural history of thalassemia intermedia. Ann N Y Acad Sci 2010;1202:214-220.
89. Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990;58:50-55.
90. Hmida S, Mojaat N, Maamar M, Bejaoui M, Mediouni M, Boukef K. Red cell alloantibodies in patients with haemoglobinopathies. Nouv Rev Fr Hematol 1994;36:363-366.
91. Pippard MJ, Callender ST, Finch CA. Ferrioxamine excretion in iron-loaded man. Blood 1982;60:288-294.
92. Thalassemia International Federation. Guidelines for the Clinical Management of Thalassemia. Strovolos, Cyprus, Thalassemia International Federation, 2004.
93. Taher A, El Rassi F, Isma'Eel H, Koussa S, Inati A, Cappellini MD. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008;93:1584-1586.
94. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusiondependent thalassemia and sickle cell disease patients. Blood 2005;106:1460-1465.
95. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, Robins E, Lindeman R. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005;105:855-861.
96. Treadwell MJ, Weissman L. Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. Semin Hematol 2001;38(Suppl 1): 77-84.
97. Cappellini MD. Overcoming the challenge of patient compliance with iron chelation therapy. Semin Hematol 2005;42(Suppl 1):19-21.
98. Pootrakul P, Sirankapracha P, Sankote J, Kachintorn U, Maungsub W, Sriphen K, Thakernpol K, Atisuk K, Fucharoen S, Chantraluksri U, Shalev O, Hoffbrand AV. Clinical trial of deferiprone iron chelation therapy in β-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003;122:305-310.
99. Cappellini MD, Cohen A, Piga A, Bejaoui M, Perrotta S, Agaoglu L, Aydinok Y, Kattamis A, Kilinc Y, Porter J, Capra M, Galanello R, Fattoum S, Drelichman G, Magnano C, Verissimo M, Athanassiou-Metaxa M, Giardina P, Kourakli-Symeonidis A, Janka-Schaub G, Coates T, Vermylen C, Olivieri N, Thuret I, Opitz H, Ressayre-Djaffer C, Marks P, Alberti D. A phase 3 study of deferasirox (ICL670), a oncedaily oral iron chelator, in patients with β-thalassemia. Blood 2006;107:3455-3462.
100. Vichinsky E, Onyekwere O, Porter J, Swerdlow P, Eckman J, Lane P, Files B, Hassell K, Kelly P, Wilson F, Bernaudin F, Forni GL, Okpala I, Ressayre-Djaffer C, Alberti D, Holland J, Marks P, Fung E, Fischer R, Mueller BU, Coates T; Deferasirox in Sickle Cell Investigators. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007;136:501-508.
101. Taher AT, Porter JB, Viprakasit V, Kattamis A, Chuncharunee S, Sutcharitchan P, Siritanaratkul N, Galanello R, Karakas Z, Lawniczek T, Habr D, Ros J, Zhu Z, Cappellini MD. Deferasirox effectively reduces iron overload in nontransfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013;92:1485-1493.
102. Rienhoff HY Jr, Viprakasit V, Tay L, Harmatz P, Vichinsky E, Chirnomas D, Kwiatkowski JL, Tapper A, Kramer W, Porter JB, Neufeld EJ. A phase 1 dose escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 2011;96:521-525.
103. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Pediatr Hematol Oncol 2005;27:380-385.
104. Neufeld EJ, Galanello R, Viprakasit V, Aydinok Y, Piga A, Harmatz P, Forni GL, Shah FT, Grace RF, Porter JB, Wood JC, Peppe J, Jones A, Rienhoff HY Jr. A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. Blood 2012;119:3263-3268.
105. Olivieri NF. Reactivation of fetal hemoglobin in patients with β-thalassemia. Semin Hematol 1996;33:24-42.
106. Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol 2005;84:441-446.
107. Panigrahi I, Dixit A, Arora S, Kabra M, Mahapatra M, Choudhry VP, Saxena R. Do alpha deletions influence hydroxyurea response in thalassemia intermedia? Hematology 2005;10:61-63.
108. Pakbaz Z, Treadwell M, Yamashita R, Quirolo K, Foote D, Quill L, Singer T, Vichinsky EP. Quality of life in patients with thalassemia intermedia compared to thalassemia major. Ann N Y Acad Sci 2005;1054:457-461.
109. Khoury B, Musallam KM, Abi-Habib R, Bazzi L, Ward ZA, Succar J, Halawi R, Hankir A, Koussa S, Taher AT. Prevalence of depression and anxiety in adult patients with β-thalassemia major and intermedia. Int J Psychiatry Med 2012;44:291-303.
110. Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in β-thalassemia intermedia: breaking the silence. Thromb Res 2012;130:695-702.